Immuron 미래 성장

Future 기준 확인 2/6

Immuron (는) 각각 연간 22.4% 및 59.7% 수익과 수익이 증가할 것으로 예상됩니다.

주요 정보

22.4%

수익 성장률

n/a

EPS 성장률

Biotechs 수익 성장	15.5%
매출 성장률	59.7%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	26 Sep 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

CHIA:IMC - 애널리스트의 미래 추정치 및 과거 재무 데이터 (AUD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2026	15	-4	N/A	N/A	1
6/30/2025	6	-8	N/A	N/A	1
6/30/2024	5	-7	-6	-6	N/A
3/31/2024	4	-5	-5	-5	N/A
12/31/2023	4	-4	-4	-4	N/A
9/30/2023	3	-4	-3	-3	N/A
6/30/2023	2	-4	-3	-3	N/A
3/31/2023	1	-3	-2	-2	N/A
12/31/2022	1	-3	-2	-2	N/A
9/30/2022	1	-3	-2	-2	N/A
6/30/2022	1	-3	-3	-3	N/A
3/31/2022	1	-4	-3	-3	N/A
12/31/2021	0	-4	-4	-4	N/A
9/30/2021	0	-6	-4	-4	N/A
6/30/2021	0	-8	-4	-4	N/A
3/31/2021	1	-8	N/A	N/A	N/A
12/31/2020	1	-7	-4	-4	N/A
9/30/2020	2	-5	-4	-4	N/A
6/30/2020	3	-3	-3	-3	N/A
3/31/2020	3	-4	N/A	N/A	N/A
12/31/2019	3	-5	-3	-3	N/A
9/30/2019	3	-5	-2	-2	N/A
6/30/2019	2	-5	-2	-2	N/A
3/31/2019	2	-4	-1	-1	N/A
12/31/2018	2	-3	-1	-1	N/A
9/30/2018	2	-3	-2	-2	N/A
6/30/2018	2	-3	-4	-4	N/A
3/31/2018	2	-4	N/A	-6	N/A
12/31/2017	2	-5	N/A	-8	N/A
9/30/2017	2	-6	N/A	-8	N/A
6/30/2017	1	-7	N/A	-7	N/A
3/31/2017	1	-8	N/A	-5	N/A
12/31/2016	1	-6	N/A	-4	N/A
9/30/2016	1	-6	N/A	-5	N/A
6/30/2016	1	-7	N/A	-5	N/A
3/31/2016	1	-5	N/A	-5	N/A
12/31/2015	1	-4	N/A	-5	N/A
9/30/2015	1	-4	N/A	-4	N/A
6/30/2015	1	-3	N/A	-3	N/A
3/31/2015	1	-3	N/A	-3	N/A
12/31/2014	1	-2	N/A	-3	N/A
9/30/2014	1	-2	N/A	-3	N/A
6/30/2014	1	-2	N/A	-3	N/A
3/31/2014	1	-3	N/A	-2	N/A
12/31/2013	0	-3	N/A	-2	N/A

애널리스트 미래 성장 예측

수입 대 저축률: IMC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: IMC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: IMC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: IMC 의 수익(연간 59.7% ) Australian 시장( 5.8% 보다 빠르게 성장할 것으로 예상됩니다. 5.8% 연간).

고성장 수익: IMC 의 수익(연간 59.7% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: IMC 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Immuron 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million.

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

New major risk - Share price stability

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited Receives FDA Approval for Travelan IND Application

Immuron Limited Submits IND Application To FDA for Travelan

Insufficient new directors

Immuron Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.038 loss in FY 2021)

Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research

Insufficient new directors

Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Insufficient new directors

Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: AU$0.038 loss per share (vs AU$0.017 loss in FY 2020)

Executive Vice Chairman Peter Anastasiou has left the company

Insufficient new directors

Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program

First half 2021 earnings released: AU$0.026 loss per share (vs AU$0.009 loss in 1H 2020)

New 90-day low: AU$0.21

New 90-day low: AU$0.21

Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E

Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli

Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine

New 90-day low: AU$0.23

Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea

Full year earnings released - AU$0.017 loss per share

Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.

New 90-day high - AU$0.87

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견